Metagenomi Statistics
Total Valuation
Metagenomi has a market cap or net worth of $158.47 million. The enterprise value is -$126.12 million.
| Market Cap | 158.47M |
| Enterprise Value | -126.12M |
Important Dates
The next estimated earnings date is Monday, August 12, 2024, before market open.
| Earnings Date | Aug 12, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Metagenomi has 37.46 million shares outstanding. The number of shares has increased by 521.79% in one year.
| Shares Outstanding | 37.46M |
| Shares Change (YoY) | +521.79% |
| Shares Change (QoQ) | +520.86% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.35 |
| Forward PS | 3.85 |
| PB Ratio | 0.57 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.75, with a Debt / Equity ratio of 0.17.
| Current Ratio | 4.75 |
| Quick Ratio | 4.73 |
| Debt / Equity | 0.17 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | $199,401 |
| Profits Per Employee | -$326,034 |
| Employee Count | 237 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 6.05 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 35.58 |
| Average Volume (20 Days) | 103,217 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Metagenomi had revenue of $47.26 million and -$77.27 million in losses. Loss per share was -$2.06.
| Revenue | 47.26M |
| Gross Profit | n/a |
| Operating Income | n/a |
| Pretax Income | n/a |
| Net Income | -77.27M |
| EBITDA | n/a |
| EBIT | n/a |
| Loss Per Share | -$2.06 |
Balance Sheet
The company has $332.65 million in cash and $48.06 million in debt, giving a net cash position of $284.59 million or $7.60 per share.
| Cash & Cash Equivalents | 332.65M |
| Total Debt | 48.06M |
| Net Cash | 284.59M |
| Net Cash Per Share | $7.60 |
| Equity (Book Value) | 275.63M |
| Book Value Per Share | 7.36 |
| Working Capital | 264.94M |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | -163.51% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Metagenomi does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -521.79% |
| Shareholder Yield | -521.79% |
| Earnings Yield | -48.76% |
| FCF Yield | n/a |
Analyst Forecast
The average price target for Metagenomi is $17.83, which is 321.51% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $17.83 |
| Price Target Difference | 321.51% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |